EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroids

Torbjörn Bäckström iD, Sahruh Turkmen, Roshni Das, Magnus Doverskog, Thomas P Blackburn

Journal of Internal Medicine · 2023-09 · 294 (3) · 281-294

DOI: 10.1111/joim.13705 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 30.07.2023. Verfasst von Torbjörn Bäckström und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, University of Umeå, Umeå, Sweden. Hauptthemen laut MEDLINE: Neurosteroids, Cognitive Dysfunction, Alzheimer Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of cognitive dysfunction, dementia, and neurodegenerative disorders such as Alzheimer's disease (AD) is increasing in parallel with an aging population. Distinct types of chronic stress are thought to be instrumental in the development of cognitive impairment in central nervous system (CNS) disorders where cognitive impairment is a major unmet medical need. Increased GABAergic tone is a mediator of stress effects but is also a result of other factors in CNS disorders. Positive GABA‐A receptor modulating stress and sex steroids (steroid‐PAMs) such as allopregnanolone (ALLO) and medroxyprogesterone acetate can provoke impaired cognition. As such, ALLO impairs memory and learning in both animals and humans. In transgenic AD animal studies, continuous exposure to ALLO at physiological levels impairs cognition and increases degenerative AD pathology, whereas intermittent ALLO injections enhance cognition, indicating pleiotropic functions of ALLO. We have shown that GABA‐A receptor modulating steroid antagonists (GAMSAs) can block the acute negative cognitive impairment of ALLO on memory in animal studies and in patients with cognitive impairment due to hepatic encephalopathy. Here we describe disorders affected by steroid‐PAMs and opportunities to treat these adverse effects of steroid‐PAMs with novel GAMSAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurosteroidsCognitive DysfunctionAlzheimer DiseaseAnimalsHumansAgedReceptors, GABA-APregnanolonegamma-Aminobutyric Acid

Stichwörter der Autor:innen

GABA-A receptorallopregnanolonedementiamemoryneurosteroids

Substanzen

Receptors, GABA-ANeurosteroidsPregnanolonegamma-Aminobutyric Acid

Autor:innen und Institutionen

  • Department of Clinical Sciences, University of Umeå, Umeå, Sweden.
  • Umecrine Cognition AB, Solna, Sweden.

ORCID-Profile: Torbjörn Bäckström

Zitieren

APA

Bäckström, T., Turkmen, S., Das, R., Doverskog, M., & Blackburn, T. P. (2023). The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroids. Journal of Internal Medicine, 294(3), 281-294. https://doi.org/10.1111/joim.13705

Vancouver

Bäckström T, Turkmen S, Das R, Doverskog M, Blackburn TP. The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroids. Journal of Internal Medicine. 2023;294(3):281-294. doi:10.1111/joim.13705

BibTeX
@article{Bckstrm2023,
  author = {Bäckström, Torbjörn and Turkmen, Sahruh and Das, Roshni and Doverskog, Magnus and Blackburn, Thomas P},
  title = {The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroids},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {294},
  number = {3},
  pages = {281--294},
  doi = {10.1111/joim.13705}
}
Kostenlos starten →